Additional supporting evidence has come from another study showing that coadministration of anti-PDL1 antibody is capable of unleashing the antitumor effects of a polyvalent neoantigen vaccine against intracerebral CT2A27, an aggressive mouse brain tumor. Here, CD274 is linked to brain neoplasm.